Understanding Iatrogenic CNS Injury 

What is an Iatrogenic CNS Injury?

Iatrogenic means an illness, injury, or health problem caused by medical treatment, a diagnostic procedure, or a doctor's actions. The word comes from Greek roots meaning "created by a healer". 

When a person experiences severe adverse effects, withdrawal, protracted withdrawal, or neurological damage from prescription medications, what they are suffering from is not a mental health relapse or return of a baseline condition. It is an iatrogenic injury affecting the central nervous system (CNS).¹ 

Terms like BIND (Benzodiazepine-Induced Neurological Dysfunction)² and neuro-adaptation injury help validate what patients experience: a state where chemical trauma has heavily disrupted the brain's receptors, creating a hyper-sensitised, unstable nervous system that is struggling to recalibrate.

 Damage to the CNS is not restricted to benzodiazepines, but can occur through the use of any medication that affects the CNS. Chemical trauma can be triggered or aggravated by a wide array of other commonly prescribed medications. These include:

Benzodiazepines, Prescription Sedatives & Z Drugs: Long-term use or unmonitored changes cause severe down-regulation of GABA receptors - the brain's primary braking system - leading to profound neurological overexcitation.³ 

Antidepressants & Psychotropics (SSRIs, SNRIs, Tricyclics, Tetracyclics): Altering or stopping serotonin and norepinephrine reuptake inhibitors forces the brain to rapidly readapt its neurotransmitter systems⁴ . Abrupt cessation or fast tapers can trigger severe antidepressant discontinuation syndrome, emotional numbness, prolonged akathisia, and persistent withdrawal symptoms.⁵ ⁶ 

Antipsychotics: These powerful dopamine and serotonin antagonists can cause profound neurological alterations, extrapyramidal symptoms, and severe withdrawal or receptor supersensitivity effects when reduced or discontinued.⁷ ⁸

Gabapentinoids (Pregabalin & Gabapentin): Frequently prescribed for nerve pain, anxiety, and epilepsy, gabapentinoids (such as gabapentin and pregabalin) heavily impact calcium channels. Rapid cessation or reduction can trigger severe withdrawal syndromes, intense psychological distress and profound central nervous system instability. ⁹

Fluoroquinolone Antibiotics: Certain broad-spectrum antibiotics (such as ciprofloxacin or levofloxacin) are known to provoke sudden, severe neurotoxicity, musculoskeletal damage, and central nervous system disruption, sometimes referred to as 'floxing'.¹⁰  ¹¹  

Antiemetics: standard rescue medications - particularly dopamine-blocking antiemetics like metoclopramide (Reglan) - can trigger acute extrapyramidal reactions, inner restlessness and severe akathisia. ¹² Other antiemetics like ondansetron (Zofran) work on serotonin (5-HT3) receptors. Because psychiatric drugs disrupt serotonin regulation (especially during tapering), serotonin and dopamine targeting medications increase risk of nervous system instability and injury. 

Recognising the Symptoms 

CNS injury manifests through a vast array of intense physical and psychological symptoms that doctors often mistakenly misdiagnose as psychiatric illness:

Severe Physical Sensations: Internal vibrations, buzzing, burning skin, muscle spasms, and profound psychological exhaustion. 

Intense neurological distress: unrelenting akathisia (a deep internal state of physical and mental torment), cognitive fog, and severe depersonalisation. 

Sensory hyper-reactivity: extreme sensitivity to light, sound, environmental stimuli, supplements, and additional medications or foods. 

Safe Navigation & Recovery

The Danger of Rapid Cessation

Cold turkeys, linear reductions, or overly fast percentage cuts shock an already vulnerable nervous system, causing and exacerbating severe acute waves of CNS injury.¹⁵ ¹⁶  

Informed, slow tapering

Healing requires time, patience, and gentle, hyperbolic reductions. We advise readers to familiarise themselves with gold-standard international frameworks - such as the Ashton Manual and the Maudsley Deprescribing Guidelines - which emphasise patient-led pacing to protect the nervous system. 

References

1. National Institute for Health and Care Excellence. (2022). Medicines associated with dependence or withdrawal symptoms: Safe prescribing and withdrawal management for adults (NICE guideline NG215). https://www.nice.org.uk/guidance/ng215

2. Ritvo, A. D., Foster, D. E., Huff, C., Finlayson, A. J. R., Silvernail, B., & Martin, P. R. (2023). Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey. PLOS ONE, 18(6), e0285584. https://doi.org/10.1371/journal.pone.0285584

3. National Institute for Health and Care Excellence. (2022). Medicines associated with dependence or withdrawal symptoms: Safe prescribing and withdrawal management for adults (NICE guideline NG215). https://www.nice.org.uk/guidance/ng215

4. Davies, J., & Read, J. (2019). A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? Addictive Behaviors, 97, 111–118. https://doi.org/10.1016/j.addbeh.2018.08.027

5. Horowitz, M. A., & Taylor, D. (2022). Distinguishing relapse from antidepressant withdrawal: Clinical practice and antidepressant discontinuation studies. BJPsych Advances, 28(5), 297–311. https://doi.org/10.1192/bja.2021.62

6. Rennwald, A., & Hengartner, M. P. (2025). Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: A systematic review with meta-narrative synthesis. Epidemiology and Psychiatric Sciences, 34, e29. https://doi.org/10.1017/S204579602500023X

7. Brandt, L., Bschor, T., Henssler, J., Müller, F., & others. (2020). Antipsychotic withdrawal symptoms: A systematic review and meta-analysis. Frontiers in Psychiatry, 11, 569912. https://doi.org/10.3389/fpsyt.2020.569912

8. Chouinard, G., & Chouinard, V.-A. (2008). Atypical antipsychotics: Metabolic and extrapyramidal adverse effects and withdrawal symptoms. Current Opinion in Psychiatry, 21(4), 353–359. https://doi.org/10.1097/YCO.0b013e3283060e5a

9. National Institute for Health and Care Excellence. (2022). Medicines associated with dependence or withdrawal symptoms: Safe prescribing and withdrawal management for adults (NICE guideline NG215). https://www.nice.org.uk/guidance/ng215

10. Baggio, D., Ananda-Rajah, M., & others. (2024). Safety of fluoroquinolones: An update. Australian Prescriber, 47, 8–13. https://doi.org/10.18773/austprescr.2024.001

11. Anwar, M., et al. (2023). Depressive and other adverse CNS effects of fluoroquinolones. [Journal details as published]. https://pmc.ncbi.nlm.nih.gov/articles/PMC10459424/

12. Van Gool, A. R., Doorduijn, J., & Seynaeve, C. (2010). Severe akathisia as a side effect of metoclopramide. Pharmacy World & Science, 32(6), 704–706. https://doi.org/10.1007/s11096-010-9444-3

13. Becker, H. C. (1998). Kindling in alcohol withdrawal. Alcohol Health & Research World, 22(1), 25–33. https://pmc.ncbi.nlm.nih.gov/articles/PMC6761822/

14. Lader, M., & Morton, S. (1991). Benzodiazepine withdrawal syndromes. Journal of the Royal Society of Medicine, 84(10), 608–611. https://pmc.ncbi.nlm.nih.gov/articles/PMC1293394/

15. National Institute for Health and Care Excellence. (2022). Medicines associated with dependence or withdrawal symptoms: Safe prescribing and withdrawal management for adults (NICE guideline NG215). https://www.nice.org.uk/guidance/ng215

16. Horowitz, M. A., & Taylor, D. (2019). Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry, 6(6), 538–546. https://doi.org/10.1016/S2215-0366(19)30032-X